Under 30 wa Kiherehere Ya Kukimbila Madawa Kaeni Nyumbani

[SIZE=7]AstraZeneca vaccine: Under-30s should be offered alternative jab, government advisers say[/SIZE]
[SIZE=6]More than 20 million doses of the Oxford/AstraZeneca vaccine have been administered across the UK with only 79 cases of extremely rare blood clots[/SIZE]

Read more:
[li]How worried should you be about possible AstraZeneca vaccine blood clot link?[/li][li]AstraZeneca vaccine: Unusual blood clots ‘very rare’ side effect of jab, EMA review finds[/li][li]Scientists address concerns over AstraZeneca vaccine and blood clot reports[/li][/ul]
At a briefing on Wednesday afternoon, deputy chief medical officer Jonathan Van-Tam said the decision on the vaccine was a “course correction” to the UK vaccine programme.

June Raine, chief executive of the Medicines and Healthcare products Regulatory Agency said the UK’s “monitoring systems” were “now detecting a potential side effect of the Covid-19 vaccine AstraZeneca in an extremely small number of people.
“The evidence is firming up, and our review has concluded that while it’s a strong possibility more work is needed to establish, beyond all doubt that the vaccine has caused these side effects.”

She added: “Based on the current evidence, the benefits of the Covid-19 vaccine AstraZeneca against Covid-19 and its associated risks, hospitalisation and death, continues to outweigh the risks for the vast majority of people. The balance of benefits and risks is very favourable for older people, but it is more finely balanced for the younger people.”

The MHRA is advising any patient who experiences symptoms four days after vaccination should seek medical advice. This includes a severe or persistent headache or blurred vision, shortness of breath, chest pain, leg swelling or persistent abdominal pain, or unusual skin bruising or pinpoint spots beyond the injection site.